Shortage Loophole Enabled Mass Market Semaglutide

The core advantage was not better medicine, it was turning a shortage loophole into a mass market price cut. During the semaglutide shortage, compounding let telehealth sellers offer monthly treatment for about $300, far below Wegovy’s roughly $1,300 list price, which made paid ads convert and opened obesity treatment to cash pay patients who could not afford branded pricing. That price gap is what moved Fella from a niche clinic into a scaled consumer acquisition machine.

• The economics were simple. A patient clicked an ad, filled out a short intake form, got a remote clinical review, and received medication by mail. At $300 per month, the service looked like a reachable subscription. At branded Wegovy pricing, the same funnel is much harder to scale because far fewer patients can pay cash.
  1 sacra 2 novocare
• This was a market wide opening, not an AIOS only trick. FDA shortage policy created room for semaglutide compounding, then the February 2025 shortage resolution and spring 2025 enforcement deadlines shut that window. That is why revenue across GLP-1 telehealth players became tightly linked to regulatory timing, not just marketing execution.
  2 novocare 5 fda
• The comparison also shows why branded resale is less attractive. In the UK, AIOS rebuilt growth by selling branded Wegovy and Mounjaro at cost through Bolt, but that looks more like a pharmacy business with about 20% gross margins, versus the much richer economics telehealth platforms can earn when they control the compounded or fulfillment layer.
  1 sacra

The next phase is a shift from loophole driven price arbitrage to distribution scale and channel control. As branded GLP-1 supply normalizes and manufacturers tighten legal and commercial control, winners will be the telehealth operators that can still acquire patients cheaply, route them into regulated pharmacy supply, and keep enough service margin after the drug maker takes most of the medication revenue.